MD

Mediwound LtdNASDAQ MDWD Stock Report

Last reporting period 30 Jun, 2024

Updated 05 Nov, 2024

Last price

Market cap $B

0.186

Micro

Exchange

XNAS - Nasdaq

MDWD Stock Analysis

MD

Uncovered

Mediwound Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-49/100

Low score

Market cap $B

0.186

Dividend yield

Shares outstanding

9.475 B

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

View Section: Eyestock Rating